Global Hemophilia Drugs Market 2016-2020
Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.
Technavio’s analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Hemophilia Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the global hemophilia drugs market: Baxalta, Bayer, CSL Behring, Novo Nordisk, and Pfizer.
Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, and UniQure Biopharma.
Commenting on the report, an analyst from Technavio’s team said: “One trend gaining traction in this market is increase in technological innovations. Currently, most of the hemophilia therapeutics available in the market are short-acting i.e., used only for when the individual suffers from bleeding. Apart from this, it is also observed that many of these products exhibit immunogenic reactions, which result in a reduced therapeutic effect of these products.”
According to the report, drugs with prolonged action will drive the market. Earlier, parenteral formulations for treating hemophilia B required frequent administration of replacement factors. Drugs with favorable pharmacokinetic profiles, including prolonged mechanism of action are fast gaining acceptance among physicians and individuals. These long-acting formulations reduce the need for repeated dosing of medications, reducing injection site pain. ALPROLIX by Biogen is one such drug.
Further, the report states that the diagnosis rates of hemophilia are very low, especially in the developing countries like China and India. In the developed regions such as Germany, Australia, and the US, the disease diagnosis rate is more than 80%. However, in developing countries such as China, India, and Indonesia, disease diagnosis rates are 56%, 12%, and 4%, respectively. The low diagnosis rate of hemophilia in developing countries is due to inadequate treatment facilities, limited disease knowledge, and a shortage of treatment supplies.
Baxalta, Bayer, CSL Behring, Novo Nordisk, Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, UniQure Biopharma.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook